Featured Research

from universities, journals, and other organizations

HPV DNA Test Identifies Cervical Pre-cancerous Disease In Developing Countries With 90% Success Rate

Date:
September 25, 2008
Source:
Queen Mary, University of London
Summary:
Results of the first study to determine the accuracy of a new rapid screening test for HPV created specifically for use in the developing world, have shown it to be 90 percent accurate in detecting precancerous cervical disease when tested on a group of local women in Shanxi province, eastern China.

Results of the first study to determine the accuracy of a new rapid screening test for HPV (Human Papilloma Virus), created specifically for use in the developing world, have shown it to be 90 per cent accurate in detecting precancerous cervical disease when tested on a group of local women in Shanxi province, eastern China.

The results, published online September 22 in Lancet Oncoloy, conclude that the test; careHPV, could provide an effective primary screening method for cervical cancer prevention in rural and low-resource settings.

Designed by Attila Lorincz - Professor of Molecular Epidemiology at Barts and The London School of Medicine and Dentistry - to be conducted in rural settings by personnel with minimal training, careHPV can detect 14 high-risk types of carcinogenic Human Papilloma Virus in around 2.5 hours. Cytologic screening available in North America and Europe – where an appropriate infrastructure exists - has led to a 50 – 80 per cent reduction in mortality, but it has previously not been possible to translate this expertise to the developing world where taking smears properly and reading them has been problematic.

Working in collaboration with the Program for Appropriate Technologies in Health (PATH, Seattle WA, USA) and funded by the Bill and Melina Gates Foundation to lead research into a new HPV DNA screening test which was rapid, simple, and affordable, Professor Lorincz created the careHPV test because there was no such provision deemed appropriate for use in low resource settings.

careHPV is a signal-amplification assay adapted from HC2 (the Hybrid Capture test, widely regarded as the gold standard routine HPV DNA test, and initially created by Professor Lorincz for use in developed countries). It requires only a small area (approximately 25cm x 30cm) of clean bench-top work space, no mains electricity or running water, and can be performed by non-technical support staff in approximately two and half hours. The short assay time allows testing and clinical follow-up on the same day. The prototype was used in an outcomes study in Shanxi province, China with 2,388 local women aged 30 to 54. The ability of the careHPV test to detect precancerous cells was found to be 90.0 per cent, whilst 84.2 per cent of the women without precancerous disease were identified as negative by the test.

Professor Lorincz said: "The clinical performance of my new HPV test in China appears promising, it is based on decades of research and I hope it will be employed widely to save the lives of millions of women. The new test needs to be studied in many countries to confirm its suitability for cervical cancer screening on the global stage"

Cervical cancer is the second most common cancer in women with about 500,000 new cases and 300,000 deaths every year. Almost 100 per cent of these cancers are caused by carcinogenic Human Papilloma Virus and - because it is possible to stop the infectious cycle and therefore the disease - are completely preventable. Vaccination against HPV shows promise for future generations and is currently being implemented in the UK, mostly in young school-aged girls.

However, the current vaccine has some significant limitations because it is most effective against only two HPV types (16 and 18) that account for approximately 75 per cent of cervical cancers. In addition the vaccine is ineffective in women who have been exposed to the virus (a majority of women over the age of about 20). Thus screening remains the main hope for the current generation of women aged 20 years or above and will need to be continued for at least the next 30 years.


Story Source:

The above story is based on materials provided by Queen Mary, University of London. Note: Materials may be edited for content and length.


Cite This Page:

Queen Mary, University of London. "HPV DNA Test Identifies Cervical Pre-cancerous Disease In Developing Countries With 90% Success Rate." ScienceDaily. ScienceDaily, 25 September 2008. <www.sciencedaily.com/releases/2008/09/080921201718.htm>.
Queen Mary, University of London. (2008, September 25). HPV DNA Test Identifies Cervical Pre-cancerous Disease In Developing Countries With 90% Success Rate. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2008/09/080921201718.htm
Queen Mary, University of London. "HPV DNA Test Identifies Cervical Pre-cancerous Disease In Developing Countries With 90% Success Rate." ScienceDaily. www.sciencedaily.com/releases/2008/09/080921201718.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins